Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 5;14(7):e078335.
doi: 10.1136/bmjopen-2023-078335.

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration

Kristy P Robledo  1 , Shilo Lefresne  2   3 , Yu Yang Soon  4   5   6 , Arjun Sahgal  7 , Mark B Pinkham  8 , Alan Nichol  2 , Ross Andrew Soo  5   6 , Ambika Parmar  9 , Fiona Hegi-Johnson  10 , Mark Doherty  11 , Benjamin J Solomon  10 , David B Shultz  12 , Ivan Wk Tham  13 , Adrian G Sacher  12 , Jeremy Tey  5   6 , Cheng Nang Leong  5   6 , Wee Yao Koh  5   6 , Yiqing Huang  5   6 , Yvonne Li En Ang  5   6 , Jiali Low  5   6 , Clement Yong  6   14 , Mei Chin Lim  6   14 , Ai Peng Tan  6   14 , Chee Khoon Lee  4 , Cheryl Ho  2   3
Affiliations

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration

Kristy P Robledo et al. BMJ Open. .

Abstract

Background: Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) gene are a heterogeneous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer-generation targeted therapies in the central nervous system. We present a protocol for an individual patient data (IPD) prospective meta-analysis to evaluate whether the addition of stereotactic radiosurgery (SRS) before osimertinib treatment will lead to better control of intracranial metastatic disease. This is a clinically relevant question that will inform practice.

Methods: Randomised controlled trials will be eligible if they include participants with BM arising from EGFR-mutant NSCLC and suitable to receive osimertinib both in the first-line and second-line settings (P); comparisons of SRS followed by osimertinib versus osimertinib alone (I, C) and intracranial disease control included as an endpoint (O). Systematic searches of Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform's Search Portal will be undertaken. An IPD meta-analysis will be performed using methodologies recommended by the Cochrane Collaboration. The primary outcome is intracranial progression-free survival, as determined by response assessment in neuro-oncology-BM criteria. Secondary outcomes include overall survival, time to whole brain radiotherapy, quality of life, and adverse events of special interest. Effect differences will be explored among prespecified subgroups.

Ethics and dissemination: Approved by each trial's ethics committee. Results will be relevant to clinicians, researchers, policymakers and patients, and will be disseminated via publications, presentations and media releases.

Prospero registration: CRD42022330532.

Keywords: Clinical trials; Meta-Analysis; ONCOLOGY; Patients; Radiation oncology; Respiratory tract tumours.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SL: research funding and honoraria from AstraZeneca. YYS: honoraria from AstraZeneca and Janssen. AGS: research grants (institution) from Elekta AB, Varian, Seagen and BrainLAB; consulting fees from Varian, Elekta (Gamma Knife Icon), BrainLAB, Merck, Abbvie and Roche; honoraria from AstraZeneca, Elekta AB, Varian, BrainLAB, Accuray and Seagen. MBP: speaker fees from AZ, BMS, MSD and Roche. AN: research grants from Varian Medical Systems. RAS: advisory board with Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma Biotechnology, Roche, Taiho, Takeda, Thermo Fisher and Yuhan Corporation; research grant from Astra-Zeneca and Boehringer Ingelheim. FHJ: clinical trial funding, received honoraria and participated in advisory boards for Astra Zeneca; received payments and honoraria from BeiGene and MSD for lectures and presentations; supported by the Peter Mac Foundation and the Victorian Cancer Agency. BJS: advisory board/honoraria from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Merck, Bristol Mysers Squibb, Janssen, Amgen and Eli Lilly. IWKT: honorarium from Elekta and MSD. CH: advisory boards with Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda; research grants from AstraZeneca, EMD Serono and Roche. CKL: advisory board with Amgen, Astra Zeneca, GSK, Merck KGA, Norvatis, Pfizer, Roche, Takeda, Boehringer-Ingelheim and Yuhan; research funding (institution) from Astra Zeneca, Roche, Merck KGA and Amgen. KPR, AP, MD, DBS, AGS, JT, CNL, WYK, YH, YLEA, JL, CY, MCL and APT have no competing interests. CH, SL, FHJ, CKL, YYS, RAS and IWKT are study chairs on the included trials.

References

    1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. . Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol 2004;22:2865–72. 10.1200/JCO.2004.12.149 - DOI - PubMed
    1. Rangachari D, Yamaguchi N, VanderLaan PA, et al. . Brain metastases in patients with EGFR-Mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108–11. 10.1016/j.lungcan.2015.01.020 - DOI - PMC - PubMed
    1. Suh JH, Kotecha R, Chao ST, et al. . Current approaches to the management of brain metastases. Nat Rev Clin Oncol 2020;17:279–99. 10.1038/s41571-019-0320-3 - DOI - PubMed
    1. Andrews DW, Scott CB, Sperduto PW, et al. . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665–72. 10.1016/S0140-6736(04)16250-8 - DOI - PubMed
    1. Sahgal A, Ruschin M, Ma L, et al. . Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues. Neuro Oncol 2017;19:ii2–15. 10.1093/neuonc/nox001 - DOI - PMC - PubMed

Publication types

MeSH terms